Clinical Trial Update: Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose interleukin-2 for immune-associated amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: UNKNOWN